Kiora CEO covers taxes with 1,906 share transfer

Kiora Pharmaceuticals President and CEO Brian M. Strem reported a tax-related share disposition.

Rhea-AI Filing Summary

Kiora Pharmaceuticals President and CEO Brian M. Strem reported a tax-related share disposition. On April 1, 2026, he transferred 1,906 shares of Common Stock at $1.95 per share to cover taxes by delivering shares instead of cash. After this tax-withholding disposition, he directly holds 60,692 shares of Kiora common stock. This was not an open-market sale or purchase but a routine mechanism tied to equity compensation.

Insider Trade Summary

Exercise Price or Tax Liability: 1,906 shares

Exercise Price or Tax Liability 1 txn

Insider Strem Brian M.

Role President and CEO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	1,906	$1.95	$4K

Holdings After Transaction: Common Stock — 60,692 shares (Direct)

Key Figures

Tax-withholding shares: 1,906 shares Implied share value: $1.95 per share Post-transaction holdings: 60,692 shares

3 metrics

Tax-withholding shares 1,906 shares Common Stock delivered for tax obligations on April 1, 2026

Implied share value $1.95 per share Value used for 1,906-share tax-withholding disposition

Post-transaction holdings 60,692 shares Direct Kiora common stock held by CEO after disposition

Key Terms

tax-withholding disposition, Payment of exercise price or tax liability by delivering securities, non-derivative

3 terms

tax-withholding disposition financial

"transaction_action: "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Payment of exercise price or tax liability by delivering securities financial

"transaction_code_description: "Payment of exercise price or tax liability by delivering securities""

non-derivative financial

"transaction_type: "non-derivative""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kiora (KPRX) CEO Brian Strem report in this Form 4?

Brian M. Strem reported a tax-withholding disposition of 1,906 Kiora common shares. The shares were delivered to cover tax obligations related to equity compensation, rather than sold in the open market.

How many Kiora (KPRX) shares were involved in the CEO’s tax withholding?

The Form 4 shows 1,906 shares of Kiora common stock transferred at $1.95 per share. These shares were used to satisfy tax liabilities, not to execute a discretionary open-market trade.

How many Kiora (KPRX) shares does the CEO hold after this transaction?

Following the tax-withholding disposition, Brian M. Strem directly holds 60,692 shares of Kiora common stock. This figure reflects his remaining direct ownership after 1,906 shares were delivered to cover tax obligations.

Was this Kiora (KPRX) CEO transaction a market sale or purchase?

No, the Form 4 characterizes it as a tax-withholding disposition with transaction code F. That means shares were delivered to satisfy tax liabilities, not actively sold or bought on the open market.

What does transaction code F mean in the Kiora (KPRX) Form 4 filing?

Transaction code F signifies payment of an exercise price or tax liability by delivering securities. In this case, 1,906 Kiora shares were transferred to cover taxes tied to the CEO’s equity compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 04:45 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Strem Brian M.

(Last) (First) (Middle)

C/O KIORA PHARMACEUTICALS, INC.

169 SAXONY RD., SUITE 212

(Street)

ENCINITAS CALIFORNIA 92024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KIORA PHARMACEUTICALS INC [ KPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		F		1,906	D	$1.95	60,692	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Net share settlement, shares withheld for employee tax obligation upon vesting of restricted stock.

	/s/ Melissa Tosca, Attorney-in-Fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)